KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, Thierry Facon, Tadao Ishida, Roman Hájek, Ivan Špička, Joanna Romejko-Jarosinska, Vladimir Vorobyev, Britta Besemer, Sevgi Kalayoğlu Beşışık, Pawel Robak, Tomas Jelinek, Hartmut Goldschmidt, Thomas Martin, Mohamad Mohty, Sandrine Macé, Ercem Kodas, Christina Tekle, Andrea T Shafer, Philippe Moreau

Blood 147(23) 2760-2769

PMID41758929
PMCIDPMC13277651
DOI10.1182/blood.2025030120
发表日期2026-02-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Quadruplet therapy with Isa-VRd (isatuximab, Velcade [bortezomib], Revlimid [lenalidomide], and dexamethasone) followed by Isa-Rd in the randomized phase 3 IMROZ study provided a significant progression-free survival benefit to transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). In the primary analysis, more Isa-VRd/Isa-Rd-treated patients achieved minimal residual disease (MRD) negativity and MRD-negative complete response (CR) at any time point than patients receiving VRd followed by Rd. Here, we report landmark analysis results of MRD negativity over time and its impact on clinical outcomes in IMROZ. Treatment with Isa-VRd/Isa-Rd led to deeper responses, with higher rates of MRD negativity and MRD-negative CR at the end of induction and during maintenance vs VRd/Rd, up to 60 months of follow-up. Benefit with Isa-VRd/Isa-Rd was observed across key patient subgroups, including older (>70 years) and frail patients. Time to progression (TTP) was significantly prolonged with Isa-VRd/Isa-Rd vs VRd/Rd in patients who converted from MRD negative to MRD positive at any time point. In a landmark analysis of the time of conversion to MRD positivity, TTP in patients who converted from MRD negative at the end of induction to MRD positive also favored Isa-VRd/Isa-Rd. Evaluating MRD status of patients at >1 time point may therefore be useful to support decisions on treatment selection and treatment continuation/discontinuation. Our findings on the degree of MRD negativity and MRD-negative CR benefit achieved during induction and maintenance by patients receiving Isa-VRd/Isa-Rd vs VRd/Rd extend the IMROZ primary analyses and further support Isa-VRd as standard of care for frontline treatment of transplant-ineligible patients with NDMM. This trial was registered at www.clinicaltrials.gov as #NCT03319667.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2. PFS in patients who were MRD negative at 6 months (induction phase). (A) PFS in MRD-negative patients at the 10 − 5 sensitivity threshold ( P = .0784). (B) PFS in MRD-negative patients at the 10 – 6 sensitivity threshold ( P = .3264).

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 6

Figure 6. PFS for MRD-negative CR patients and MRD negativity rates over time. (A) PFS for MRD-negative CR patients (10 – 5 ) in the ITT population ( P = .0336). MRD negativity was defined as a patient having at least 1 MRD-negative assessment at any time point. Patients were MRD negative and achieved CR at any point in the study. (B) Landmark MRD negativity rates (10 – 5 ) at different time points in patients who achieved CR. †Bortezomib was dropped and patients received Isa-Rd and Rd, respectively. ‡Patients received monthly isatuximab. MRD-neg, minimal residual disease–negative.

A

Progression-free survival

Figure 6 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Cumulative MRD negativity rates in the ITT population. MRD negativity rates at 10 −5 sensitivity threshold (A) and 10 − 6 sensitivity threshold (B). All time points were calculated using the number of patients who achieved initial MRD negativity at that time point divided by the ITT (Isa-VRd/Isa-Rd, n = 265; VRd/Rd, n = 181); the rate is cumulative over time. †The last MRD-negative result in the VRd/Rd arm occurred at 48 months; beyond this, the cumulative rate did not increase and can be considered a flat line.
非 KM Figure
Figure 3Figure 3. Landmark MRD negativity analyses during induction and maintenance phases. MRD negativity at the induction phase and at various time points during the maintenance phase. †Bortezomib was dropped and patients received Isa-Rd and Rd, respectively. ‡Patients received monthly isatuximab. MRD-neg, minimal residual disease–negative.
非 KM Figure
Figure 4Figure 4. Landmark analysis: conversion from MRD negativity at induction phase to MRD positivity during maintenance phase. Conversion rates of MRD negativity at the induction phase to MRD positivity at various time points during the maintenance phase. Only patients who achieved MRD negativity (left side of the graph) during induction are depicted here and were evaluated for conversion to MRD positivity at any point during the maintenance phase (right side of the graph, shown from 12 through 36 months). ∗The number of assessments from MRD-negative patients at induction who had repeat MRD assessment at the given time point. †Bortezomib was dropped and patients received Isa-Rd and Rd, respectively. ‡Patients received monthly isatuximab. MRD-neg, minimal residual disease–negative; MRD-pos, minimal residual disease–positive.
非 KM Figure
Figure 5Figure 5. TTP. (A) After conversion from MRD negativity at the induction phase to MRD positivity during the maintenance phase ( P = .0036). (B) After conversion from MRD negativity to MRD positivity at any time point ( P = .0041).
非 KM Figure
Figure 7Figure 7. Sustained MRD negativity rates. MRD negativity at 10 – 5 sensitivity threshold (A) and 10 – 6 sensitivity threshold (B) in the ITT population. ∗A total of 13, 16, and 39 MRD-positive patients, who were MRD negative (10 – 5 ) at some point on study, were missing in sustained MRD negativity assessments at ≥12, ≥24, and ≥36 months in the Isa-VRd/Isa-Rd arm, whereas this number was 9, 15, and 38 patients in the VRd/Rd arm, respectively. MRD-neg, minimal residual disease–negative.
非 KM Figure